Yahoo Web Search

Search results

  1. People also ask

  2. In contrast to erythromycin and clarithromycin, azithromycin does not seem to interact with SLCO1B1 or SLCO1B3 . Azithromycin has been shown to be a weak substrate for CYP3A4, to be minimally metabolized by the enzyme, and to neither induce nor inhibit CYP3A4 activity .

  3. For drug interaction purposes, the inhibitors and inducers of CYP3A metabolism listed above can alter serum concentrations of drugs that are dependent upon the CYP3A subfamily of liver enzymes, including CYP3A4, for elimination or activation. These classifications are based upon US Food and Drug Administration (FDA) guidance.

  4. Dec 16, 2015 · CYP3A4 Inhibitors. Drugs that inhibit CYP3A4 activity (Table 3) will usually inhibit the metabolism and increase the plasma concentrations of the CYP3A4 substrate medications listed in Table 1.

    • How does azithromycin inhibit CYP3A4?1
    • How does azithromycin inhibit CYP3A4?2
    • How does azithromycin inhibit CYP3A4?3
    • How does azithromycin inhibit CYP3A4?4
    • How does azithromycin inhibit CYP3A4?5
  5. Aug 1, 2014 · Importantly, azithromycin is neither metabolized by nor an inhibitor of CYP3A4 and therefore, does not interact with many commonly used medications that are oxidatively metabolized by CYP3A4 (Shakeri-Nejad & Stahlmann, 2006).

  1. People also search for